Doctors said that in a large clinical trial, Eli Lilly's weight loss drug significantly reduced patients' weight, which is of great importance to patients and has a profound impact on the field.
At the European Association for the Study of Diabetes meeting held in Vienna, doctors reported that the American pharmaceutical company's tablet orforglipron reduced the weight of adult obese patients by 11.2%, and the side effects were consistent with currently available vaccines.
Eli Lilly presented the full data from the drug's main obesity trial at the conference and published it in the New England Journal of Medicine

At the European Association for the Study of Diabetes meeting held in Vienna, Eli Lilly's weight loss drug orforglipron reduced the weight of obese adult patients by 11.2% in a large clinical trial. Doctors stated that this achievement is significant for patients and will have a profound impact on the field of weight loss medications. The drug's side effects are consistent with currently available vaccines, and Eli Lilly also presented the full data from the major obesity trial at the meeting, which was published in the New England Journal of Medicine

礼来礼来 片剂 orforglipron 使成人肥胖患者的体重减轻了 11.2%

礼来礼来片剂 orforglipron 使成人肥胖患者的体重减轻了 11.2%